Erratum: Data exclusivity for biologics (Nature Reviews Drug Discovery (2011) 10 (15-16) DOI: 10.1038/nrd3277);Data exclusivity for biologics

Nature Reviews Drug Discovery

Volumn 10, Issue 1, 2011, Pages 15-16

  Grabowski, Henry ^a   Long, Genia ^b   Mortimer, Richard ^b  

^a DUKE UNIVERSITY   (United States)

^b ANALYSIS GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST; DRUG DEVELOPMENT; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE POLICY; INSURANCE; LAW; MATHEMATICAL MODEL; MONTE CARLO METHOD; PATENT; PRIORITY JOURNAL; UNITED STATES;

EID: 78650839980     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3466     Document Type: Erratum

References (3)

1. Title VII of the Patient Protection and Affordable Care Act of 2010, Pub. L. No. 111-48, Improving Access to Innovative Medical Therapies-Subtitle (2010).
2. Grabowski, H. Follow-on biologics: data exclusivity and the balance between innovation and competition. Nature Rev. Drug Discov. 7, 479-488 (2008).
3. Federal Trade Commission (FTC). Emerging Health Care Issues: Follow-on Biologic Drug Competition. Federal Trade Commission Report | June 2009. FTC website [online], http://www.ftc.gov/os/2009/06/ P083901biologicsreport.pdf (2009).